CombiGene AB (publ) (COMBI.ST)
CombiGene AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Lidingö, SE. The stock last traded at $2.47, down 3.89% on the session, giving a market capitalisation of $48.9M. Its beta of 1.22 implies it has historically moved more than the broad market.
Headquartered in Lidingö, Sweden, CombiGene AB (publ) was established in 1999 and specializes in pioneering gene therapy solutions for severe, life-altering medical conditions. The company is currently advancing two primary gene therapy candidates in its pipeline. CG01, a treatment targeting epilepsy, is undergoing preclinical trials that include detailed biodistribution and toxicology assessments. Its second candidate, CGT2, is under development for addressing lipodystrophy. CombiGene also maintains strategic alliances, including a licensing and collaborative agreement with Lipigon Pharmaceuticals AB to create a gene therapy for partial lipodystrophy, and a partnership with Spark Therapeutics for the advancement of adeno-associated virus (AAV) based gene therapies.
CombiGene AB (publ) is most often compared with the following Healthcare names: